TickerTalks
Browse all tickers →
TickerTalks›$TEVA
TETEVA

Teva Pharmaceutical Industries Limited

$TEVA·$46B·Drug Manufacturers - Specialty & Generic·Healthcare
$41.50+0.9%YTD+25.1%1Y+111.4%
Price updated 3h ago·X counts updated 5d ago
TETEVA
$TEVATeva Pharmaceutical Industries Limited
$41.50+0.95%215 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $TEVA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

215X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $TEVA's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 72% of tracked names.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-08

Teva delivered clean Ph2a data for TEV-408 (IL-15) in celiac disease meeting goal of providing clear POC with consistent benefit and stat-sig improvements in key endpoints. BofA raised PT to $43 from $41 with Buy.

Read what X is saying about $TEVA

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $TEVA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersEvent coming upAI verdict · as of 2026-10-03

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Teva's TEV-408 celiac Phase 2a hit the mark — BofA bumped the PT, Nov 3 earnings is the next test.

Teva Pharmaceutical Industries is a global generics-and-specialty-pharma giant whose 2026 pipeline story centers on specialty assets — TEV-408 (IL-15) in celiac disease, ecopipam for Tourette syndrome, and biosimilars. The specialty pipeline is finally generating data.

  • The P&L reflects transition: Q2 revenue was flat YoY at $4.14B at a 3.6% operating margin and EPS of -$0.49, with the most recent EPS missing by 75% — these are the numbers of a generics business compressing while specialty hasn't yet replaced it on scale.
  • The specific catalyst is TEV-408 Phase 2a: clean proof-of-concept in celiac disease with stat-sig endpoint improvement, plus BofA raising PT to $43 from $41 with a Buy — this is the kind of pipeline validation that resets specialty-revenue expectations materially.

At 94% of its 52-week range going into Nov 3 earnings, the setup is late-cycle on specialty-pipeline momentum. A clean specialty revenue beat plus ecopipam Tourette-syndrome commercial-readiness commentary is the trigger; another large generics EPS miss or any ecopipam regulatory curveball is the invalidation.

Agrees with X sentimentThe clean Phase 2a POC and BofA PT bump are specific institutional datapoints that line up with the sector-wide pipeline-ingrowth story.

What to watch: Nov 3 Q3 earnings — specialty-pharma revenue, generics direction, operating margin, ecopipam launch commentary, and FY27 guide. Specialty growth plus ecopipam clarity is the trigger; another generics miss is the invalidation.

On the calendar: 2026-11-03 — Q3 earnings

event ahead 30dpipeline wins

Read the AI verdict on $TEVA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Teva Pharmaceutical is the world's largest generics drug maker, with a branded specialty portfolio including Austedo (neurological) and Ajovy (migraine).

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $TEVA.

Drug Manufacturers - Specialty & Generic · Healthcare

Specialty pharma is bifurcating — GLP-1 adjacent programs attract premium valuations while generic manufacturers face pricing erosion from FDA approval backlogs clearing. Biosimilar launches of adalimumab (Humira), ustekinumab, and etanercept are accelerating branded erosion timelines, while mid-tier specialty pharma focuses on complex generics (ophthalmic, inhalation) to sustain margins.

What this means for $TEVA

Direct beneficiary — Teva Pharmaceutical is the world's largest generics drug maker, with a branded specialty portfolio including Austedo (neurological) and Ajovy (migraine).

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
57.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
10.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
17.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
5.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
9.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
52.5%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
2.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$0.02$0.08-75.0%
Q1 2026Apr 29, 2026$0.53$0.50+6.0%
Q4 2025Jan 28, 2026$0.96$0.65+47.7%
Q3 2025Nov 5, 2025$0.78$0.68+14.7%
Next earningsTue, Nov 3·consensus EPS $0.72

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$4.1B-0.8%52.0%3.6%$-0.49$307.0M
Q1 FY26$4.0B+2.3%49.5%16.4%$0.32$-208.0M
Q4 FY25$4.7B+11.4%56.4%6.4%$0.42$1.0B
Q3 FY25$4.5B+3.4%51.4%19.7%$0.38$233.0M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$16.5B$16.4B – $16.5B$1.99$1.91 – $2.089
FY27$17.3B$17.2B – $17.4B$3.06$2.96 – $3.139
FY28$18.1B$17.5B – $18.4B$3.43$2.95 – $3.909
FY29$18.9B$18.6B – $19.3B$3.82$3.73 – $3.924
FY30$19.6B$19.2B – $20.0B$4.27$4.18 – $4.394

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.96%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+7.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+20.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 1.1B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.825-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 18Brian SavageInterim Chief Legal Officer7.3K sh$285KSellSep 18Roberto MignoneDirector367.6K sh$14.4MSellAug 21Amir WeissChief Accounting Officer9.4K sh$355KSellAug 21Ronit Satchi-fainaroDirector415 sh$15KSellAug 17Evan LippmanEVP, Business Development18.6K sh$680KSellAug 5Zaks Tal ZviDirector17 sh$593SellAug 3Placid JoverSee "Remarks"12.8K sh$447KSellAug 3Eric A HughesSee "Remarks"25.6K sh$892KSellJun 18Matthew ShieldsEVP, Global Operations10.0K sh$322KSellJun 11Kalif Eliyahu SharonCFO106.6K sh$3.6M
1–10 of 14
+ 25 other (16 exempts · 9 awards) in window

See when $TEVA insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsOct 83
8-KMaterial agreementSep 168-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

Teva Pharmaceutical Industries Limited (TEVA) filed an 8-K on September 16, 2026, disclosing both a material definitive agreement (Item 1.01) and the creation of a direct financial obligation (Item 2.03). The excerpt shows only the cover page. This combination is characteristic of a new debt facility, term loan, or bond issuance — material for Teva given its ongoing deleveraging program and complex capital structure.

424B5Prospectus supplement (offering)Sep 11424B5
AI summary

Teva Pharmaceutical Finance Netherlands II, III, and IV B.V. (subsidiaries of Teva Pharmaceutical Industries Limited) priced a ~$4.9 billion equivalent multi-tranche bond offering: €1B at 4.250% due March 2033, €500M at 4.625% due September 2036, $1B at 5.500% due January 2034, $1B at 5.750% due January 2037, and $1.2B at 5.250% due January 2032, all guaranteed unconditionally by Teva. Interest on USD notes is semi-annual; Euro notes annual. Notes include make-whole call provisions and change-of-control put at 101%. This large-scale debt refinancing (~$4.9B equivalent) is transformative for Teva's maturity profile, extending debt into 2032–2037 at fixed rates.

8-KPress release / Reg FDSep 118-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Teva Pharmaceutical's finance subsidiaries (Teva Finance II, III, IV) entered an Underwriting Agreement on September 9, 2026, for a $4.9 billion equivalent multi-tranche bond offering: €1B at 4.250% due 2033, €500M at 4.625% due 2036, $1B at 5.500% due 2034, $1B at 5.750% due 2037, and $1.2B at 5.250% due 2032 — all guaranteed unconditionally by Teva Pharmaceutical Industries Limited. Pricing was announced via press release on September 10, 2026. This is a major debt capital raise totaling ~$4.9B equivalent across EUR and USD markets, materially increasing Teva's leverage but likely aimed at refinancing near-term maturities given Teva's large existing debt load.

424B5Prospectus supplement (offering)Sep 8424B5
AI summary

Teva Pharmaceutical filed a preliminary 424B5 for a multi-currency, multi-tranche notes offering through three subsidiaries: Teva Finance II (euro-denominated 2033 and 2036 notes), Teva Finance III (USD 2034 notes), and Teva Finance IV (USD 2032 notes), with all obligations unconditionally guaranteed by Teva Pharmaceutical Industries. Specific amounts and coupon rates were not yet finalized in this preliminary filing. This large-scale debt refinancing is expected to partially address Teva's substantial debt burden as it continues executing its restructuring plan.

8-KMaterial eventSep 38-K — Item 3.03
AI summary

Teva Pharmaceutical Industries Limited announced it will terminate its American Depositary Share (ADS) program, effective at the open of business on September 14, 2026. Each existing ADS (1 ADS = 1 ordinary share, par value NIS 0.10) will be mandatorily exchanged for one NYSE-listed ordinary share of equivalent economic value. The amendment to the Deposit Agreement with Citibank (as depositary) was executed August 31, 2026, providing the mandatory exchange mechanism. This is a significant corporate action that simplifies Teva's U.S. listing structure by eliminating the ADS wrapper; existing ADS holders become direct ordinary share holders with no economic change.

8-KShareholder voteMay 288-K — Item 5.07: Shareholder vote
8-KPress release / Reg FDApr 298-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 8 other (2 routine 8-Ks · 2 10-Qs · 1 8-A12B/A · 1 25-NSE) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Teva to Host R&D Day on Wednesday, November 11 in New York Cityglobenewswire.com·4d agoTEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophreniazacks.com·4d agoTeva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcriptseekingalpha.com·7d agoFDA Approves Teva's New Once-Monthly Schizophrenia Injectionbenzinga.com·8d agoTeva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZAmarketbeat.com·8d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$PCRX$ACB$ZTS$ZYBT$ELAN$EVO$INDV$EBS
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport